HILLEVAX INC (HLVX) Stock Price & Overview
NASDAQ:HLVX • US43157M1027
Current stock price
The current stock price of HLVX is 2.09 USD. Today HLVX is down by -0.48%. In the past month the price increased by 1.46%. In the past year, price increased by 16.11%.
HLVX Key Statistics
- Market Cap
- 104.793M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.43
- Dividend Yield
- N/A
HLVX Stock Performance
HLVX Stock Chart
HLVX Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to HLVX. When comparing the yearly performance of all stocks, HLVX is one of the better performing stocks in the market, outperforming 74.76% of all stocks.
HLVX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to HLVX. No worries on liquidiy or solvency for HLVX as it has an excellent financial health rating, but there are worries on the profitability.
HLVX Earnings
HLVX Forecast & Estimates
6 analysts have analysed HLVX and the average price target is 2.04 USD. This implies a price decrease of -2.39% is expected in the next year compared to the current price of 2.09.
HLVX Groups
Sector & Classification
HLVX Financial Highlights
Over the last trailing twelve months HLVX reported a non-GAAP Earnings per Share(EPS) of -1.43. The EPS increased by 57.82% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -40.65% | ||
| ROE | -48.1% | ||
| Debt/Equity | 0 |
HLVX Ownership
HLVX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.02 | 367.796B | ||
| AMGN | AMGEN INC | 15.37 | 189.224B | ||
| GILD | GILEAD SCIENCES INC | 15.72 | 172.517B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.4 | 110.97B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.97 | 79.171B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 47.19 | 42.718B | ||
| INSM | INSMED INC | N/A | 33.416B | ||
| NTRA | NATERA INC | N/A | 27.358B | ||
| BIIB | BIOGEN INC | 10.73 | 25.385B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.56 | 25.059B | ||
| MRNA | MODERNA INC | N/A | 20.21B | ||
| INCY | INCYTE CORP | 12.41 | 19.119B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.11B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About HLVX
Company Profile
HilleVax, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel vaccines. The company is headquartered in Boston, Massachusetts and currently employs 14 full-time employees. The company went IPO on 2022-04-29. The firm's programs, HIL-214 and HIL-216, are virus-like particle (VLP) based vaccine candidates in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. HIL-214 consists of VLPs which are designed to mimic the structure of norovirus and are co-formulated with an alum adjuvant to enhance immunogenicity and stability of the VLPs in solution. HIL-214 is administered intramuscularly via prefilled syringes and has demonstrated stability at standard refrigeration temperatures of four degrees Celsius for 24 months. The firm has in-licensed HIL-216 from Chengdu Kanghua Biological Products Co., Ltd. (Kangh), a Chinese company. Its license provides world-wide rights to the vaccine outside of the Chinese market. HIL-216 includes six common norovirus genotypes: GI.1, GII.2, GII.3, GII.4, GII.6 and GII.17.
Company Info
IPO: 2022-04-29
HILLEVAX INC
321 Harrison Ave, Suite 500
Boston MASSACHUSETTS US
Employees: 14
Phone: 16172135054
HILLEVAX INC / HLVX FAQ
Can you describe the business of HILLEVAX INC?
HilleVax, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel vaccines. The company is headquartered in Boston, Massachusetts and currently employs 14 full-time employees. The company went IPO on 2022-04-29. The firm's programs, HIL-214 and HIL-216, are virus-like particle (VLP) based vaccine candidates in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. HIL-214 consists of VLPs which are designed to mimic the structure of norovirus and are co-formulated with an alum adjuvant to enhance immunogenicity and stability of the VLPs in solution. HIL-214 is administered intramuscularly via prefilled syringes and has demonstrated stability at standard refrigeration temperatures of four degrees Celsius for 24 months. The firm has in-licensed HIL-216 from Chengdu Kanghua Biological Products Co., Ltd. (Kangh), a Chinese company. Its license provides world-wide rights to the vaccine outside of the Chinese market. HIL-216 includes six common norovirus genotypes: GI.1, GII.2, GII.3, GII.4, GII.6 and GII.17.
Can you provide the latest stock price for HILLEVAX INC?
The current stock price of HLVX is 2.09 USD. The price decreased by -0.48% in the last trading session.
Does HILLEVAX INC pay dividends?
HLVX does not pay a dividend.
How is the ChartMill rating for HILLEVAX INC?
HLVX has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
On which exchange is HLVX stock listed?
HLVX stock is listed on the Nasdaq exchange.
Can you provide the PE ratio for HLVX stock?
HILLEVAX INC (HLVX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.43).
Would investing in HILLEVAX INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on HLVX.